A multi-faceted intervention including antenatal corticosteroids to reduce neonatal mortality associated with preterm birth: a case study from the Guatemalan Western Highlands

Ana Garces, Elizabeth M McClure, Lester Figueroa, Sayury Pineda, K Michael Hambidge, Nancy F Krebs, Vanessa R Thorsten, Dennis D Wallace, Fernando Althabe, Robert L Goldenberg, Ana Garces, Elizabeth M McClure, Lester Figueroa, Sayury Pineda, K Michael Hambidge, Nancy F Krebs, Vanessa R Thorsten, Dennis D Wallace, Fernando Althabe, Robert L Goldenberg

Abstract

Background: The Global Network for Women's and Children's Health Research undertook a cluster-randomized trial to assess the impact of a multi-faceted intervention to identify women at high-risk of preterm birth at all levels of care, to administer corticosteroids to women and refer for facility delivery compared with standard care. Of the seven sites that participated in the ACT trial, only two sites had statistically significant reductions in the neonatal mortality among the target group of <5th percentile infants, and of the two, Guatemala's improvement in neonatal mortality was by far the largest.

Methods: We used data available from the ACT trial as well as pretrial data in an attempt to understand why neonatal mortality may have decreased in the intervention clusters in <5(th) percentile infants in Chimaltenango, Guatemala. The intervention and control clusters were compared in regards to ACS use, the various types of medical care, outcomes in facility and community births and among births in various birth weight categories.

Results: Neonatal mortality decreased to a greater extent in the intervention compared to the control clusters in the <5(th) percentile infants in Guatemala during the ACT Trial. ACS use for the <5(th) percentile infants in the intervention clusters was 49.1 % compared to 13.8 % in the control clusters. Many measures of the quality of obstetric and neonatal care improved to a greater extent in the intervention compared to the control clusters during the trial. Births in facilities and births weighing 1500 to 2500 g had the greatest reduction in neonatal mortality.

Conclusions: The combination of improved care and greater ACS use may potentially account for the observed difference in neonatal mortality between the intervention and control clusters.

Trial registration: Clinicaltrials.gov: NCT01084096 .

References

    1. Blencowe H, Cousens S, Chou D, Oestergaard M, Say L, Moller AB, on behalf of the Born Too Soon Preterm Birth Action Group et al. Born too soon: the global epidemiology of 15 million preterm births. Reprod Health. 2013;10:S2. doi: 10.1186/1742-4755-10-S1-S2.
    1. National Institutes of Health . The effect of corticosteroids for fetal maturation on perinatal outcomes. Consensus Development. Washington DC: National Institutes of Health; 1994.
    1. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2006;3:CD004454.
    1. Althabe F, Belizán JM, Mazzoni A, Berrueta M, Hemingway - Foday J, et al. Antenatal corticosteroids trial in preterm births to increase neonatal survival in developing countries: study protocol. Reproductive Health. 2012;9:22.
    1. Althabe F, Belizan JM, McClure EM, Hemingway-Foday J, Berrueta M, Mazzoni A, et al. A population - based, multifaceted strategy to implement antenatal corticosteroid treatment versus standard care for the reduction of neonatal mortality due to preterm birth in low-income and middle - income countries: the ACT cluster - randomised trial. Lancet. 2015;385(9968):629-39
    1. United Nations Development Program. Cifras para el Desarrollo Humano Chimaltenango. Obtained from . accessed April 16, 2015.
    1. Ministry of Public Health and Social Assistance of Guatemala, National Statistics Institute . 2008–2009 National Maternal Infant Health Survey. Guatemala: Ministry of Public Health; 2011.
    1. Garces A, McClure EM, Chomba E, Patel A, Pasha O, Tshefu A, et al. Home birth attendants in low income countries: who are they and what do they do? BMC Pregnancy Childbirth. 2012;12:34. doi: 10.1186/1471-2393-12-34.
    1. Johnson DE, Munson DP, Thompson TR. Effect of antenatal administration of Betamethasone on hospital costs and survival of premature infants. Pediatrics. 1981;68(5):633–7.
    1. Papageorgiou AN, Desgranges MF, Masson M, Colle E, Shatz R, Gelfand MM. The antenatal use of betamethasone in the prevention of respiratory distress syndrome: a controlled double-blind study. Pediatrics. 1979;63(1):73–9.
    1. Brownfoot FC, Gagliardi DI, Bain E, Middleton P, Crowther CA. Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2013;8:CD006764.
    1. Garces A, McClure EM, Hambidge KM, Nancy F. Krebs, Figueroa L, Aguilar M, et al. Trends in perinatal deaths from 2010 to 2013 in the Guatemalan Western Highlands. Reprod Health. 2015;12(Suppl 2):S14. doi: 10.1186/1742-4755-12-S2-S14.
    1. Bose CL, Bauserman M, Goldenberg RL, Goudar SS, McClure EM, Pasha O, et al. The Global Network Maternal Newborn Health Registry: a multi-national, community-based registry of pregnancy outcomes. Reprod Health. 2015;12 Suppl 2:S1. doi: 10.1186/1742-4755-12-S2-S1.
    1. Goldenberg RL, McClure EM, Bose CL, Jobe AH, Belizán JM. Research results from a registry supporting efforts to improve maternal and child health in low and middle income countries. Reprod Health. 2015;12:54. doi: 10.1186/s12978-015-0045-4.
    1. Seale AC, Blencowe H, Zaidi A, Ganatra H, Syed S, Engmann C, et al. Neonatal Infections Estimation Team. Neonatal severe bacterial infection impairment estimates in South Asia, sub-Saharan Africa, and Latin America for 2010. Pediatr Res. 2013;74 Suppl 1:73–85. doi: 10.1038/pr.2013.207.
    1. Qazi SA, Wall S, Brandes N, Engmann C, Darmstadt GL, Bahl R. An innovative multipartner research program to address detection, assessment and treatment of neonatal infections in low-resource settings. Pediatr Infect Dis J. 2013;32(Suppl 1):S3–6. doi: 10.1097/INF.0b013e31829ff5e5.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi